To Compare Post-Extraction Use of a Novel Ethylenediaminetetraacetic Acid (EDTA) Post-operative Mouth Rinse and Daily Use EDTA Mouth Rinse and Standard 0.12% Chlorhexidine (CHX) Post-operative Mouth Rinse and Daily Use Essential Oil (EO) Mouth Rinse.

March 17, 2026 updated by: Maria L. Geisinger, DDS, MS, University of Alabama at Birmingham

A Prospective, Randomized Clinical Trial to Compare Post-extraction Use of a Novel Ethylenediaminetetraacetic Acid (EDTA) Post-operative Mouth Rinse and Daily Use EDTA Mouth Rinse and Standard 0.12% Chlorhexidine (CHX) Post-operative Mouth Rinse and Daily Use Essential Oil (EO) Mouth Rinse.

This study will compare commercially available, commonly used mouth rinses (0.12% chlorhexidine (CHX) vs. Ethylenediaminetetraacetic acid (EDTA)) for immediate post-operative and daily antiseptic use after tooth extraction and ridge preservation grafting followed by daily use of commercially available an essential oil (EO) mouthrinse and EDTA mouthrinse.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This investigator-initiated study will compare commercially available, commonly used mouth rinses for post-operative and daily antiseptic use after tooth extraction and bone grafting withing the extraction socket. Current protocols for post-extraction antiseptic use often employ the use of broad-spectrum antimicrobial mouth rinse, commonly 0.12% chlorhexidine (CHX), during the immediate post-operative period when patients are often advised not to perform mechanical oral hygiene (e.g. toothbrushing and interdental cleaning) at the surgical site. Further, approximately 25% of individuals use over-the-counter (OTC) therapeutic mouth rinses daily. Concerns have been raised about the broad-spectrum antimicrobial nature of CHX and the potential for cytotoxic effects from CHX, which can negatively impact both the microbiome and tissue healing at the extraction site. EDTA is a chelating agent that can bind to metal cations and has historically been used in OTC dentifrices (toothpastes) and mouthrinses to reduce calcification of plaque biofilm to reduce calculus (tartar) formation. Recent data evaluating the use of EDTA chelators have expanded dental healthcare professional's understanding of potential mechanisms of action of EDTA to include impacts on initial binding of primary bacterial colonizers within dental plaque biofilms to the dental pellicle.

Specific aims for this project include the prospective comparison of the following outcomes between the groups during the 12-week healing period:

  • Wound closure
  • Plaque index
  • Adverse healing events
  • Patient-reported post-operative outcomes including pain, swelling, change in daily activities, and esthetics
  • Dimensional ridge changes

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Maria L Geisinger, DDS, MS
  • Phone Number: 205-934-4984
  • Email: miagdds@uab.edu

Study Contact Backup

  • Name: Sarah Jane Startley, DMD
  • Phone Number: 205-975-8711
  • Email: ss1971@uab.edu

Study Locations

  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294-0007
        • Recruiting
        • University of Alabama at Birmingham
        • Contact:
          • Sarah Startley, DMD
          • Phone Number: 205-975-8711
          • Email: ss1971@uab.edu
        • Contact:
          • Maria Geisinger, DDS, MS
          • Phone Number: 205-934-4984
          • Email: miagdds@uab.edu
        • Principal Investigator:
          • Maria Geisinger, DDS, MS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Able to read and provide informed consent in English
  • At least 18 years old
  • Established and registered patient of the UAB School of Dentistry
  • Patients presenting with one single rooted tooth determined to need extraction and simultaneous ridge preservation bone grafting for future dental implant placement.
  • Presence of periodontally healthy, non-carious neighboring teeth and/or healthy restored dental implants on either side of the tooth planned for extraction.
  • No anticipated need for surgical and/or endodontic care at teeth adjacent to the proposed surgical site during the study period.

Exclusion Criteria:

  • Non-English speaking
  • Age less than 18 years old or older than 85 years old
  • Smokers/nicotine users (>10 cigarettes or equivalent/day)
  • Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing
  • Multiple adjacent teeth require extraction and grafting
  • Absence of adjacent teeth/implants on either side of the tooth to be extracted.
  • Documented or suspected allergy or sensitivity to any study product

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 0.12% CHX and Essential Oil mouthrinse
Other: 0.12% CHX and Essential Oil mouthrinse
0.12% CHX mouthrinse will be used to rinse for 1 minute with 15 mL twice daily starting day 1 after surgery through day 14. Patients will be instructed to use OTC essential oil mouthrinse 15mL once daily until the conclusion of the study (day 15 to day 84).
Experimental: 2.6% EDTA and 0.2% EDTA mouth rinse
Other: 2.6% EDTA and 0.2% EDTA mouth rinse
.6% EDTA mouthrinse will be used to rinse for 1 minute with 15 mL twice daily starting day 1 after surgery through day 14. Patients will be instructed to use 0.2% EDTA mouthrinse 15mL once daily until the conclusion of the study (day 15 to day 84).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The wound closure after extraction and ridge preservation grafting at 2, 4, and 8, and 12-weeks.
Time Frame: From baseline to 2 weeks, 4 weeks, 8 weeks and 12 weeks postoperatively.
Percentage of wound area closure after extraction and ridge preservation grafting at 2, 4, and 8, and 12 weeks as measured by occlusal photographs in a 1:1 magnification.
From baseline to 2 weeks, 4 weeks, 8 weeks and 12 weeks postoperatively.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plaque accumulation at tooth surfaces adjacent to the surgical site
Time Frame: From baseline to 2 weeks, 4 weeks, 8 weeks and 12 weeks postoperatively.

Plaque index at tooth surfaces adjacent to the surgical site at 2, 4, 8, and 12-weeks postoperatively as measured by the Silness and Löe plaque index at 6 sites per tooth at all remaining teeth in the dentition. These measurements will be performed by calibrated dental examiners using a periodontal probe and standardized plaque index categories.

Silness and Loe Plaque index:

Scores of 0, 1, 2, or 3 are assigned to each of 6 tooth surfaces (mesio-buccal, buccal, disto-buccal, disto-lingual, lingual, and mesio-lingual) after 1mm subgingival periodontal probe sweep. The amount of dental plaque present is classified as:

  • 0: No plaque detectable
  • 1: A thin film of plaque visible only with a probe
  • 2: Moderate accumulation of plaque visible to the naked eye at the gingival margin
  • 3: Gross plaque accumulation
From baseline to 2 weeks, 4 weeks, 8 weeks and 12 weeks postoperatively.
Patient centered outcomes using the Visual Analog Scale (VAS)
Time Frame: From baseline to 2 weeks and 4 weeks postoperatively.
Patient centered outcomes including pain, bleeding, swelling, change in daily activities at 2 weeks and 4 weeks postoperatively, using a standardized Visual Analog Scale (VAS) assessing patient-reported outcomes.
From baseline to 2 weeks and 4 weeks postoperatively.
Ridge width and hard tissue dimensional changes after 12-week postoperative healing.
Time Frame: 12 weeks
Three-dimensional ridge hard tissue dimensional changes (ridge width and height) based upon comparison of cone-beam computerized tomography (CBCT) analysis comparing pre-extraction images and images taken prior to dental implant placement (12 weeks post-extraction).
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Alabama at Birmingham

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 2, 2026

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2028

Study Registration Dates

First Submitted

September 17, 2025

First Submitted That Met QC Criteria

September 17, 2025

First Posted (Actual)

September 24, 2025

Study Record Updates

Last Update Posted (Actual)

March 20, 2026

Last Update Submitted That Met QC Criteria

March 17, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB-300015320
  • UAB Periodontology (Other Identifier: University of Alabama at Birmingham)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on 0.12% CHX and Essential Oil mouthrinse

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe